Journal of Clinical Oncology, Vol 21, Issue 4
(February), 2003: 673-678
© 2003 American Society for Clinical Oncology
Health-Related Quality-of-Life Parameters as Independent Prognostic Factors in Advanced or Metastatic Bladder Cancer
D.F. Roychowdhury,
A. Hayden,
A.M. Liepa
From Eli Lilly and Company, Indianapolis, IN.
Address reprint requests to Debasish Roychowdhury, MD, Lilly Corporate Center, Indianapolis, IN 46285, email: dfr{at}lilly.com.
Purpose: This retrospective analysis examined prognostic significance of health-related quality-of-life (HRQoL) parameters combined with baseline clinical factors on outcomes (overall survival, time to progressive disease, and time to treatment failure) in bladder cancer.
Patients and Methods: Outcome and HRQoL (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30) data were collected prospectively in a phase III study assessing gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in locally advanced or metastatic bladder cancer. Prespecified baseline clinical factors (performance status, tumor-node-metastasis staging, visceral metastases [VM], alkaline phosphatase [AP] level, number of metastatic sites, prior radiotherapy, disease measurability, sex, time from diagnosis, and sites of disease) and selected HRQoL parameters (global QoL; all functional scales; symptoms: pain, fatigue, insomnia, dyspnea, anorexia) were evaluated using Cox’s proportional hazards model. Factors with individual prognostic value (P < .05) on outcomes in univariate models were assessed for joint prognostic value in a multivariate model. A final model was developed using a backward selection strategy.
Results: Patients with baseline HRQoL were included (364 of 405, 90%). The final model predicted longer survival with low/normal AP levels, no VM, high physical functioning, low role functioning, and no anorexia. Positive prognostic factors for time to progressive disease were good performance status, low/normal AP levels, no VM, and minimal fatigue; for time to treatment failure, they were low/normal AP levels, minimal fatigue, and no anorexia. Global QoL was a significant predictor of outcome in univariate analyses but was not retained in the multivariate model.
Conclusion: HRQoL parameters are independent prognostic factors for outcome in advanced bladder cancer; their prognostic importance needs further evaluation.
Supported by Eli Lilly and Company.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
D. Cella, J. C. Cappelleri, A. Bushmakin, C. Charbonneau, J. Z. Li, S. T. Kim, I. Chen, M. D. Michaelson, and R. J. Motzer
Quality of Life Predicts Progression-Free Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib Versus Interferon Alfa
J. Oncol. Pract,
March 1, 2009;
5(2):
66 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Efficace, P. F. Innominato, G. Bjarnason, C. Coens, Y. Humblet, S. Tumolo, D. Genet, M. Tampellini, A. Bottomley, C. Garufi, et al.
Validation of Patient's Self-Reported Social Functioning As an Independent Prognostic Factor for Survival in Metastatic Colorectal Cancer Patients: Results of an International Study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer
J. Clin. Oncol.,
April 20, 2008;
26(12):
2020 - 2026.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. C. Gotay, C. T. Kawamoto, A. Bottomley, and F. Efficace
The Prognostic Significance of Patient-Reported Outcomes in Cancer Clinical Trials
J. Clin. Oncol.,
March 10, 2008;
26(8):
1355 - 1363.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E.L. Mauer, M. J.B. Taphoorn, A. Bottomley, C. Coens, F. Efficace, M. Sanson, A. A. Brandes, C. C.D. van der Rijt, H. J.J.A. Bernsen, M. Frenay, et al.
Prognostic Value of Health-Related Quality-of-Life Data in Predicting Survival in Patients With Anaplastic Oligodendrogliomas, From a Phase III EORTC Brain Cancer Group Study
J. Clin. Oncol.,
December 20, 2007;
25(36):
5731 - 5737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bottomley, C. Coens, F. Efficace, R. Gaafar, C. Manegold, S. Burgers, M. Vincent, C. Legrand, and J. P. van Meerbeeck
Symptoms and Patient-Reported Well-Being: Do They Predict Survival in Malignant Pleural Mesothelioma? A Prognostic Factor Analysis of EORTC-NCIC 08983: Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma
J. Clin. Oncol.,
December 20, 2007;
25(36):
5770 - 5776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. W. Bruner
Should Patient-Reported Outcomes Be Mandatory for Toxicity Reporting in Cancer Clinical Trials?
J. Clin. Oncol.,
December 1, 2007;
25(34):
5345 - 5347.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Watkins Bruner, C. J. Bryan, N. Aaronson, C. C. Blackmore, M. Brundage, D. Cella, P. A. Ganz, C. Gotay, P. S. Hinds, A. B. Kornblith, et al.
Issues and Challenges With Integrating Patient-Reported Outcomes in Clinical Trials Supported by the National Cancer Institute Sponsored Clinical Trials Networks
J. Clin. Oncol.,
November 10, 2007;
25(32):
5051 - 5057.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. McCarter, W. Furlong, A. C. Whitton, D. Feeny, S. DePauw, A. R. Willan, and R. D. Barr
Health Status Measurements at Diagnosis As Predictors of Survival Among Adults With Brain Tumors
J. Clin. Oncol.,
August 1, 2006;
24(22):
3636 - 3643.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bottomley and F. Efficace
Predicting survival in advanced cancer patients: is it possible with patient-reported health status data?
Ann. Onc.,
July 1, 2006;
17(7):
1037 - 1038.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. A.J. Visschedijk, B. M.J. Uitdehaag, M. Klein, E. van der Ploeg, E. H. Collette, L. Vleugels, L. E.M.A. Pfennings, E. L.J. Hoogervorst, H. M. van der Ploeg, and C. H. Polman
Value of health-related quality of life to predict disability course in multiple sclerosis
Neurology,
December 14, 2004;
63(11):
2046 - 2050.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
